APLLTD vs SAILIFE: Stock Comparison
Alembic Pharmaceuticals Limited is the larger company by market capitalisation. Alembic Pharmaceuticals Limited shows a lower P/E, a higher dividend yield and faster revenue growth, while Sai Life Sciences Limited shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APLLTD leads 8; SAILIFE leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | APLLTD | SAILIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | APLLTD | SAILIFE |
|---|---|---|
| Live Price | ₹821.75 | ₹1,457.4 |
| Day Change | 0.94% | -0.96% |
| Volume | 35,565 | 3.24 L |
| 52-Week High | ₹998 | ₹1,484.2 |
| 52-Week Low | ₹635.8 | ₹783.85 |
| Distance from 52W High | -17.66% | -1.81% |
Valuation
| Metric | APLLTD | SAILIFE |
|---|---|---|
| Market Cap | ₹16,15,257.47 L Cr | ₹30,979 Cr |
| P/E Ratio | 23.3x | 84.93x |
| P/B Ratio | 2.85x | 12.4x |
| EPS | ₹35.25 | ₹16.43 |
| Book Value | ₹288.7 | ₹117.47 |
| Dividend Yield | 1.46% | 0% |
Growth
| Metric | APLLTD | SAILIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | 4.4% | 3.9% |
| EPS Growth (TTM YoY) | 29.2% | 17.6% |
| Qtr Sales Growth | 4.41% | 3.91% |
| Qtr Profit Growth | 40.8% | 17.8% |
Profitability & Leverage
| Metric | APLLTD | SAILIFE |
|---|---|---|
| ROE | 13.4% | 15.4% |
| ROCE | 12.6% | 19.6% |
| Net Margin | 8.98% | 15.81% |
| Operating Margin | 15.2% | 28.8% |
| Debt to Equity | 0.25x | 0.12x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | APLLTD | SAILIFE |
|---|---|---|
| Promoter Holding | 69.36%▲ 0.13 pp | 32.87%▼ 0.08 pp |
| FII Holding | 4.18%▼ 0.07 pp | 19.65%▼ 1.52 pp |
| DII Holding | 15.94%▼ 0.24 pp | 32.71%▲ 1.17 pp |
| Public Holding | 10.01%▲ 0.18 pp | 13.11%▲ 0.43 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alembic Pharmaceuticals Limited and Sai Life Sciences Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.